Skip to main content
Premium Trial:

Request an Annual Quote

Yourgene Health to Provide Back-to-Work COVID-19 Testing Under UK Partnership

NEW YORK – Yourgene Health said on Tuesday that it has partnered with international payments firm Caxton and immunity passport app provider Hooha Innovations to provide back-to-work molecular COVID-19 testing for businesses in the UK.

Under the collaboration, Caxton will offer COVID-19 tests to its network of corporate clients and their employees, who can request a test using Hooha's immunity passport app Prova. Yourgene will provide sample collection kits, train healthcare professionals to take samples, and conduct the testing in its Manchester laboratory using its CE-marked, PCR-based Clarigene SARS-CoV-2 assay. Individuals will obtain their test results through the Prova app, which allows them to share them without revealing any personal information.

Yourgene said it is still on track to release a research-use-only version of the Clarigene test by the end of June and to obtain CE marking for an in vitro diagnostic kit version in July, as announced in May.

"We are proud to support this effort as the COVID-19 lab partner to this collaboration, working with  Caxton and Prova, enabling  employees  to  return to  work safely," said Yourgene CEO Lyn Rees in a statement. "We look forward to updating the market as the project progresses as we expect to launch in summer 2020."

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.